Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice

HER2/neu is an oncogene amplified and over-expressed in 20-30% of breast adenocarcinomas. Treatment with the humanized monoclonal antibody trastuzumab has shown efficacy in combination with cytotoxic agents, although resistance occurs over time. Novel approaches are needed to further increase antibo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2011-05, Vol.29 (20), p.3646-3654
Hauptverfasser:	Orlandi, Francesca, Guevara-Patiño, José A, Merghoub, Taha, Wolchok, Jedd D, Houghton, Alan N, Gregor, Polly D
Format:	Artikel
Sprache:	eng
Schlagworte:	adenocarcinoma Adenocarcinoma - immunology Adenocarcinoma - therapy Allergy and Immunology Animals Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - immunology Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antigens Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - immunology Biological and medical sciences Breast cancer breast neoplasms Cancer therapies Cancer Vaccines - administration & dosage Cancer Vaccines - immunology Chemotherapy Clinical trials Cytokines cytotoxicity Deoxyribonucleic acid DNA DNA vaccine Epitopes - immunology Female gene overexpression HER2/neu Immunization Immunotherapy Lymphocytes Lymphocytes, Tumor-Infiltrating - immunology Mammary Neoplasms, Experimental - immunology Mammary Neoplasms, Experimental - therapy Medical research Medical sciences Melanoma Metastasis Mice Mice, Inbred BALB C monoclonal antibodies Mutagenesis, Site-Directed Mutation oncogenes patients Peptides Receptor, ErbB-2 - immunology recombinant vaccines remission Signal transduction Skin cancer Trastuzumab Tumors vaccination Vaccines Vaccines, DNA - administration & dosage Vaccines, DNA - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!